Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 5/20 | 0.45 |
| ▸ | SLC1A1 | P43005 | 5/20 | 0.45 |
| ▸ | SLC1A3 | P43003 | 4/20 | 0.45 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.45 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16903919 | 0.85 | GRIK1 (0.50) | SLC1A2SLC1A1SLC1A3GRIK1GRIK2 | |
| SCHEMBL10148382 | 0.84 | GPR84 (0.52) | SLC1A2SLC1A1GRIK1GRIK2 | |
| SCHEMBL25146258 | 0.83 | SLC1A3 (0.43) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL1694215 | 0.83 | SLC1A3 (0.43) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL9678433 | 0.82 | CHRM1 (0.52) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL19371377 | 0.80 | CHRM1 (0.50) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL5031485 | 0.80 | TDP1 (0.60) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL14110749 | 0.80 | TDP1 (0.60) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL12438372 | 0.79 | GPR84 (0.52) | SLC1A2SLC1A1GRIK1GRIK2ALDH1A1 | |
| SCHEMBL8694838 | 0.79 | CHRM1 (0.48) | CHRM1AKR1A1CHRM3HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114828841-A | Use of valproic acid for reducing post-operative scarring after glaucoma surgery | 参天制药株式会社 | 2022-07-29 | — | — | CN | claimed |
| WO-2021118469-A1 | USE OF VALPROIC ACID FOR REDUCING POST-OPERATIVE SCARRING FOLLOWING A GLAUCOMA SURGERY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2021-06-17 | — | — | WO | claimed |
| US-20230058189-A1 | QUINOLIN-4-ONE AND 4(1H)-CINNOLINONE COMPOUNDS AND METHODS OF USING SAME | Frequency Therapeutics, Inc. (US) | 2023-02-23 | — | — | US | disclosed |
| US-20230015595-A1 | USE OF VALPROIC ACID FOR REDUCING POST-OPERATIVE SCARRING FOLLOWING A GLAUCOMA SURGERY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
| CN-114828841-A | Use of valproic acid for reducing post-operative scarring after glaucoma surgery | 参天制药株式会社 | 2022-07-29 | — | — | CN | disclosed |
| US-20220096639-A1 | THERMOREVERSIBLE COMPOSITIONS FOR ADMINISTRATION OF THERAPEUTIC AGENTS | Frequency Therapeutics, Inc. | 2022-03-31 | — | — | US | disclosed |
| US-11160868-B2 | Thermoreversible compositions for administration of therapeutic agents | Frequency Therapeutics, Inc. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20210300948-A1 | 1H-PYRROLE-2,5-DIONE COMPOUNDS AND METHODS OF USING THEM TO INDUCE SELF-RENEWAL OF STEM/PROGENITOR SUPPORTING CELLS | Frequency Therapeutics, Inc. | 2021-09-30 | — | — | US | disclosed |
| US-11066419-B2 | 1H-pyrrole-2,5-dione compounds and methods of using same | Frequency Therapeutics, Inc. (US) | 2021-07-20 | — | — | US | disclosed |
| WO-2021118469-A1 | USE OF VALPROIC ACID FOR REDUCING POST-OPERATIVE SCARRING FOLLOWING A GLAUCOMA SURGERY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2021-06-17 | — | — | WO | disclosed |
| US-20200316089-A1 | 1,2-DIHYDRO-3H-PYRAZOL-3-ONE COMPOUNDS AND METHODS OF USING SAME | Frequency Therapeutics, Inc. | 2020-10-08 | — | — | US | disclosed |
| US-20170252448-A1 | THERMOREVERSIBLE COMPOSITIONS FOR ADMINISTRATION OF THERAPEUTIC AGENTS | Frequency Therapeutics, Inc. | 2017-09-07 | — | — | US | disclosed |
| US-20130237602-A1 | VALPROIC ACID DRUG DELIVERY SYSTEMS AND INTRAOCULAR THERAPEUTIC USES THEREOF | ALLERGAN, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| EP-2395970-B1 | VALPROIC ACID DRUG DELIVERY SYSTEMS AND INTRAOCULAR THERAPEUTIC USES THEREOF | ALLERGAN INC (US) | 2013-04-17 | — | — | EP | disclosed |
| US-20120059060-A1 | VALPROIC ACID DRUG DELIVERY SYSTEMS AND INTRAOCULAR THERAPEUTIC USES THEREOF | ALLERGAN, INC. | 2012-03-08 | — | — | US | disclosed |
| WO-2010093564-A1 | VALPROIC ACID DRUG DELIVERY SYSTEMS AND INTRAOCULAR THERAPEUTIC USES THEREOF | ALLERGAN, INC. (US) | 2010-08-19 | — | — | WO | disclosed |
| US-20100204325-A1 | VALPROIC ACID DRUG DELIVERY SYSTEMS AND INTRAOCULAR THERAPEUTIC USES THEREOF | ALLERGAN, INC. (US) | 2010-08-12 | — | — | US | disclosed |
| US-20090111733-A1 | PAR-4 RELATED METHODS AND COMPOSITIONS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-04-30 | — | — | US | disclosed |
| US-20090111733-A1 | PAR-4 RELATED METHODS AND COMPOSITIONS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-04-30 | — | — | US | disclosed |
| WO-2008010800-A1 | PAR-4 RELATED METHODS AND COMPOSITIONS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11160868-B2 | Thermoreversible compositions for administration of therapeutic agents | MKI67, MCL1, HSPE1 | CHRM1 4879/4885AKR1A1 2463/4885CHRM3 4805/4885 |
| US-20210300948-A1 | 1H-PYRROLE-2,5-DIONE COMPOUNDS AND METHODS OF USING THEM TO INDUCE SELF-RENEWAL OF STEM/PROGENITOR SUPPORTING CELLS | MCL1, PROX1, MKI67 | CHRM1 4722/4885AKR1A1 2773/4885CHRM3 4821/4885 |
| US-20220096639-A1 | THERMOREVERSIBLE COMPOSITIONS FOR ADMINISTRATION OF THERAPEUTIC AGENTS | MKI67, MCL1, HSPE1 | CHRM1 4879/4885AKR1A1 2463/4885CHRM3 4805/4885 |
| US-20200316089-A1 | 1,2-DIHYDRO-3H-PYRAZOL-3-ONE COMPOUNDS AND METHODS OF USING SAME | DCX, MCL1, MKI67 | CHRM1 4660/4885AKR1A1 3153/4885CHRM3 4561/4885 |
| US-20090111733-A1 | PAR-4 RELATED METHODS AND COMPOSITIONS | HTR4, HTR3C, F2RL3 | CHRM1 471/4885AKR1A1 4077/4885CHRM3 226/4885 |
| US-20170252448-A1 | THERMOREVERSIBLE COMPOSITIONS FOR ADMINISTRATION OF THERAPEUTIC AGENTS | MKI67, MCL1, HSPE1 | CHRM1 4879/4885AKR1A1 2463/4885CHRM3 4805/4885 |
| US-20230058189-A1 | QUINOLIN-4-ONE AND 4(1H)-CINNOLINONE COMPOUNDS AND METHODS OF USING SAME | DCX, NES, MCL1 | CHRM1 3860/4885AKR1A1 1868/4885CHRM3 4246/4885 |
| US-11066419-B2 | 1H-pyrrole-2,5-dione compounds and methods of using same | MKI67, PROX1, DCX | CHRM1 4667/4885AKR1A1 2276/4885CHRM3 4878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.